Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 19/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29384871 | 1.00 | ERN1 (0.64) | ERN1 | |
| SCHEMBL544809 | 0.84 | ERN1 (0.78) | ERN1 | |
| SCHEMBL30689083 | 0.83 | ERN1 (0.69) | ERN1 | |
| SCHEMBL4062201 | 0.83 | ERN1 (0.69) | ERN1 | |
| SCHEMBL1405241 | 0.78 | ERN1 (1.00) | ERN1 | |
| SCHEMBL29740541 | 0.78 | ERN1 (1.00) | ERN1 | |
| SCHEMBL29371317 | 0.78 | ERN1 (1.00) | ERN1 | |
| SCHEMBL2120180 | 0.78 | ERN1 (1.00) | ERN1 | |
| SCHEMBL767476 | 0.78 | ERN1 (0.47) | ERN1 | |
| SCHEMBL29889978 | 0.78 | ERN1 (0.47) | ERN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 269 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119242254-A | Glass fiber reinforced plastic thread elastic sealant and preparation method and application thereof | 中国石油天然气集团有限公司 | 2025-01-03 | — | — | CN | claimed |
| CN-122080106-A | Oleanolic acid acylhydrazone derivative and preparation method and application thereof | — | 2026-05-26 | — | — | CN | disclosed |
| US-20260021069-A1 | ADVANTAGEOUS FLUOROBENZOFURANS FOR THE TREATMENT OF MENTAL DISORDERS OR ENHANCEMENT | TACTOGEN INC (US) | 2026-01-22 | — | — | US | disclosed |
| US-12503477-B2 | Colony stimulating factor-1 receptor (CSF-1R) inhibitors | GENZYME CORPORATION | 2025-12-23 | — | — | US | disclosed |
| US-20250382312-A1 | BORON CONTAINING PYRAZOLE COMPOUNDS, COMPOSITIONS COMPRISING THEM, METHODS AND USES THEREOF | BORAH INC (US) | 2025-12-18 | — | — | US | disclosed |
| US-20250346593-A1 | IMIDAZO(1,2-1)PYRIDINE DERIVATIVES AS RIPK2 INHIBITORS | INTERLINE THERAPEUTICS INC (US) | 2025-11-13 | — | — | US | disclosed |
| US-12466803-B2 | BCKDK inhibitors and/or degraders | PFIZER INC. (US) | 2025-11-11 | — | — | US | disclosed |
| US-12415771-B2 | Compounds for the treatment of neuromuscular disorders | NMD PHARMA A/S (DK) | 2025-09-16 | — | — | US | disclosed |
| US-12404286-B2 | Boron containing pyrazole compounds, compositions comprising them, methods and uses thereof | BORAH, INC. (US) | 2025-09-02 | — | — | US | disclosed |
| WO-2025085527-A1 | 3βHSD1 INHIBITORS AND COMPOSITIONS AND USES THEREOF | THE CLEVELAND CLINIC FOUNDATION (US) | 2025-04-24 | — | — | WO | disclosed |
| US-7244861-B2 | Benzene compound and salt thereof | EISAI CO., LTD. (JP) | 2007-07-17 | — | — | US | disclosed |
| US-7244861-B2 | Benzene compound and salt thereof | EISAI CO., LTD. (JP) | 2007-07-17 | — | — | US | disclosed |
| US-7244861-B2 | Benzene compound and salt thereof | EISAI CO., LTD. (JP) | 2007-07-17 | — | — | US | disclosed |
| US-20070149570-A1 | Piperidine derivative and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-06-28 | — | — | US | disclosed |
| EP-1780192-A1 | METHOD FOR PRODUCING DIBROMOFLUOROBENZENE DERIVATIVE | Eisai R&D Management Co., Ltd. (JP) | 2007-05-02 | — | — | EP | disclosed |
| WO-2007015588-A1 | PIPERIDINE DERIVATIVE AS TACHYKININ RECEPTOR ANTAGONIST | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-02-08 | — | — | WO | disclosed |
| US-20050059713-A1 | Aryl and heteroaryl compounds, compositions, and methods of use | VTVX HOLDINGS I LLC | 2005-03-17 | — | — | US | disclosed |
| WO-2005014534-A1 | ARYL AND HETEROARYL COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | TRANSTECH PHARMA, INC. (US) | 2005-02-17 | — | — | WO | disclosed |
| US-20040138271-A1 | Benzene compound and salt thereof | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2004-07-15 | — | — | US | disclosed |
| EP-1375472-A1 | BENZENE COMPOUND AND SALT THEREOF | Eisai Co., Ltd. (JP) | 2004-01-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12466803-B2 | BCKDK inhibitors and/or degraders | BCKDK, KHK, PDK4 | ERN1 829/4885 |
| US-20070149570-A1 | Piperidine derivative and use thereof | TACR1, OPRL1, TRPV1 | ERN1 4124/4885 |
| US-20250382312-A1 | BORON CONTAINING PYRAZOLE COMPOUNDS, COMPOSITIONS COMPRISING THEM, METHODS AND USES THEREOF | JAK3, JAK1, JAK2 | ERN1 1139/4885 |
| US-20260021069-A1 | ADVANTAGEOUS FLUOROBENZOFURANS FOR THE TREATMENT OF MENTAL DISORDERS OR ENHANCEMENT | HCN1, HCN4, CRH | ERN1 2728/4885 |
| US-20040138271-A1 | Benzene compound and salt thereof | INSR, SLC5A1, IRS1 | ERN1 2495/4885 |
| US-20250346593-A1 | IMIDAZO(1,2-1)PYRIDINE DERIVATIVES AS RIPK2 INHIBITORS | RIPK2, RIPK1, RIPK4 | ERN1 246/4885 |
| US-12415771-B2 | Compounds for the treatment of neuromuscular disorders | RYR1, CACNB1, SMN1; SMN2 | ERN1 2210/4885 |
| US-12503477-B2 | Colony stimulating factor-1 receptor (CSF-1R) inhibitors | CSF1R, CSF3R, IL1RN | ERN1 2603/4885 |
| US-12404286-B2 | Boron containing pyrazole compounds, compositions comprising them, methods and uses thereof | JAK3, JAK1, JAK2 | ERN1 1139/4885 |
| US-20050059713-A1 | Aryl and heteroaryl compounds, compositions, and methods of use | CYP2F1, CYP3A43, PNPO | ERN1 3361/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.